Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Other Non Operating Income for 4 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 12.07% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, down 6.16% year-over-year, with the annual reading at $10.7 million for FY2025, 6.16% down from the prior year.
  • Other Non Operating Income hit $2.7 million in Q4 2025 for ARS Pharmaceuticals, up from $2.0 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $3.8 million in Q1 2023 to a low of -$151000.0 in Q1 2022.
  • Historically, Other Non Operating Income has averaged $2.3 million across 4 years, with a median of $2.8 million in 2024.
  • Biggest five-year swings in Other Non Operating Income: surged 6521.28% in 2023 and later decreased 22.71% in 2024.
  • Year by year, Other Non Operating Income stood at $1.2 million in 2022, then skyrocketed by 164.99% to $3.1 million in 2023, then decreased by 1.08% to $3.0 million in 2024, then dropped by 12.07% to $2.7 million in 2025.
  • Business Quant data shows Other Non Operating Income for SPRY at $2.7 million in Q4 2025, $2.0 million in Q3 2025, and $2.7 million in Q2 2025.